Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-031-3 | CAS number: 506-30-9
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
Data source
Reference
- Reference Type:
- publication
- Title:
- Behenic acid is a cholesterol-raising saturated fatty acid in humans
- Author:
- Nilo B Cater and Margo A Denke
- Year:
- 2 001
- Bibliographic source:
- American Journal of Clinical Nutrition, 2001 v 73, No. 1, pp 41-44
Materials and methods
- Objective of study:
- toxicokinetics
- GLP compliance:
- no
Test material
- Reference substance name:
- Behenic acid (Docosanoic acid)
- IUPAC Name:
- Behenic acid (Docosanoic acid)
- Reference substance name:
- Docosanoic acid
- EC Number:
- 204-010-8
- EC Name:
- Docosanoic acid
- Cas Number:
- 112-85-6
- Molecular formula:
- C22H44O2
- IUPAC Name:
- docosanoic acid
- Details on test material:
- - Name of test material (as cited in study report): Behenic acid
- Substance type: Organic
- Physical state: Solid
Constituent 1
Constituent 2
- Radiolabelling:
- no
Test animals
- Species:
- human
- Sex:
- male
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- other: low-fat, natural foods
- Details on exposure:
- There were 3 diet periods, each lasting 3 wk. Patients lived in the metabolic ward during each dietary period and were provided with all foods and fat supplements.
Each dietary period was separated by ≥1 wk of an outpatient, ad libitum dietary period. During each of the final 4 d of each dietary period, blood was drawn after a 14-h fast. Mean lipid and lipoprotein concentrations from the final 4 d of each period were used as indicators of the subjects’ responses to the diets - Duration and frequency of treatment / exposure:
- 3 weeks
Doses / concentrations
- Remarks:
- Doses / Concentrations:
39.5% (by weight)
- No. of animals per sex per dose / concentration:
- 7
- Control animals:
- no
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- Only approximately 30% of the dietary behenic acid was absorbed.
- Type:
- distribution
- Results:
- The appearance of behenic acid in plasma triacylglycerol fatty acids as a rough measure of absorption suggests that little if any behenic acid was absorbed and distributed intact to the fatty acid pool.
- Type:
- metabolism
- Results:
- Behenic acid may be hydrolyzed shortly after absorption into shorter-chain saturated fatty acids.
- Type:
- excretion
- Results:
- Behenic acid was recovered in the feaces
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Not applicable since the use of the chemical is not in pharma products
- Details on distribution in tissues:
- Not applicable since the use of the chemical is not in pharma products
- Details on excretion:
- Not applicable since the use of the chemical is not in pharma products
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- shorter-chain saturated fatty acids
Bioaccessibility (or Bioavailability)
- Bioaccessibility (or Bioavailability) testing results:
- The present study suggests low bio-availability of behenic acid compared with other fatty acids.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): low bioaccumulation potential based on study results
1) Absorption: Only approximately 30% of the dietary behenic acid was absorbed.
2) Distribution: The appearance of behenic acid in plasma triacylglycerol fatty acids as a rough measure of absorption suggests that little if any behenic acid was absorbed and distributed intact to the fatty acid pool.
3) Metabolism: Behenic acid may be hydrolyzed shortly after absorption into shorter-chain saturated fatty acids.
4) Excretion: Behenic acid was recovered in the feaces
From the above information and considering the low bio-availability of behenic acid compared with other fatty acids; it can be concluded that the bio-accumulation potential of behenic acid appears to be low. - Executive summary:
1) Absorption: Only approximately 30% of the dietary behenic acid was absorbed.
2) Distribution: The appearance of behenic acid in plasma triacylglycerol fatty acids as a rough measure of absorption suggests that little if any behenic acid was absorbed and distributed intact to the fatty acid pool.
3) Metabolism: Behenic acid may be hydrolyzed shortly after absorption into shorter-chain saturated fatty acids.
4) Excretion: Behenic acid was recovered in the feaces.
From the above information and considering the low bio-availability of behenic acid compared with other fatty acids; it can be concluded that the bio-accumulation potential of behenic acid appears to be low.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
